For instance, in glioblastoma, exosomes delivering CRISPR/Cas9 tools targeting mutant KRAS G12C have demonstrated the ability to knock out the mutant allele, reinstating the tumor’s temozolomide resistance (Zhao et al., 2024). This evidence concerns the gene KRAS and neoplasm.